Vanessa Mirsky Email and Phone Number
Vanessa Mirsky work email
- Valid
- Valid
Vanessa Mirsky personal email
My 20+ career as a biopharmaceutical executive has always been about positive social impact balanced with profitability, whether I am advising global market access clients on how to best get their medicines reimbursed and satisfy payers' needs to make their medicines accessible, or problem-solving for a company with a bold mission to do something good, in a way that's never been done before, but still be profitable. The only way to move something forward is to go head on into fear and the unknown, but being successful at accomplishing new things is always a team sport. A creative generalist at heart, I enjoy pursuing first-of-their-kind, go-to-market strategic partnerships with international single and multi-payer health systems, providers and payers. Healthcare is hard and highly complex, which requires multi-disciplinary thinking and experience to make genuine advancements in the delivery of value-based, affordable care. As someone who gets energy from working with others, I am highly networked across the healthcare ecosystem, and regarded as a global healthcare expert with developed, trusted relationships across insurers, payers, providers and health technology assessment (HTA) bodies in the US and internationally.Work Hard. Be Kind to Others. Live Your Values Every Day. Success Will Follow.
Oneoncology
View-
Vp, Life Sciences Data StrategyOneoncology Jan 2024 - PresentNashville, Tennessee, UsLead the data monetization strategy for OneOncology's Data Solutions business that leverages a robust set of EHR data across OneOncology's network of practices. Bring together Clinical, Data & Analytics and Corporate Strategy to deliver data-driven insights through execution of RWD/RWE projects in partnership with life sciences companies.
-
Strategic AdvisorCcx Aug 2023 - Jan 2024Zug, Zug, ChAdvised commercial team of a digital market access platform on global payer partnerships, HTA facilitation, and access contracts -
Senior Director, Corporate Strategy & Global Payer PartnershipsEqrx (Acquired By Revolution Medicines) Oct 2021 - Jan 2024Reporting to the office of the CEO, led the commercial international payer partnerships team in the execution of first-of-their kind collaborations in support of EQRx's corporate mission and vision. Executed first population health partnership in cancer with NHS England in the UK.
-
Director Payer PartnershipsEqrx (Acquired By Revolution Medicines) Nov 2020 - Oct 2021Co-led the execution of the first innovative US payer partnership for EQRx with a large regional payer, supporting a proof point for the viability of the EQRx commercial model
-
Global Head, HtaTreeage Software, Llc Jun 2015 - Nov 2020Williamstown, Massachusetts, UsResponsible for business development to grow the healthcare software business. Developed the strategy and led the execution, increasing annual revenues by 30% and expanding into new markets globally. -
Head Of Global P&R, Market Access Strategy (Prma Is Now Avalere Health)Prma Consulting Ltd Mar 2009 - May 2015Fleet, Hampshire, GbLed global commercialization strategy engagements (US, EU5 and emerging markets) to develop foundational P&R and pricing strategy to support commercialization of early and late stage assets across a breadth of orphan and non-orphan therapeutic areas spanning oncology, infectious disease and autoimmune. PRMA Consulting was acquired by Fishawack, which became Avalere.Sample Engagements:Go/No-Go Decision Support for a Phase 2 renal disease drug based on P&R/market access opportunities and risk assessment in the US and EU5.Recent Oncology P&R Landscape Trends in the US and EU5 across 9 scope products, including a mix of orphan drugs and non-orphan drugs, comparing first-to-market vs. later launch reimbursement outcomes, and learnings from manufacturers who both succeeded and failed in satisfying reimbursement authorities.HTA Analysis in Inflammatory Bowel Disease (Crohn’s disease and ulcerative colitis) to critically understand the P&R landscape for marketed drugs, including infliximab, adalimumab, certolizumab pegol, and golimumab.Emerging Markets Opportunity Assessment for an HCV asset in Phase 1 development which resulted in identifying the top 5 emerging markets, based on key clinical and economic factors. -
DirectorVsm Consulting - Life Sciences Commercialization And Clinical Development Strategy Nov 2006 - Mar 2012Freelance Commercialization strategy consulting to support clinical development and market launch activities for pharmaceutical, biotech, medical device companies. Sample Engagements:Oncology Managed Care Contracting Strategy – Assessed the potential of contracting, determined the optimal approach for managing varied customers needs, and characterized the opportunity at large cancer centers for an anti-emetic therapy.Oncology Early Stage Clinical Development Strategy – Completed market assessment due diligence on colorectal and renal cancer tumor types, including current and pipeline competitor analysis, clinical development hurdles, unmet needs, and near-term future trends in managed care and healthcare policy, to determine appropriate clinical development paths for two Phase I compounds.
-
Senior Consultant, Life Sciences PracticeDeloitte Feb 2006 - Aug 2006Worldwide, OoLed HEOR change management initiative led by C-suite executives at a large, global pharmaceutical manufacturer. US commercialization expert informing private equity due diligence engagements across biotech and device companies.Sample Engagements:Private Equity Acquisition Due Diligence – Executed a financial due diligence engagement on behalf of a private equity client interested in acquiring a medical device spin-off from a large healthcare supply company.Health Outcomes Group Reorganization – Developed strategic recommendations to improve organizational structure and function of the Health Outcomes group within a mid-tier pharmaceutical company, in order to prioritize health outcomes in clinical development planning such that reimbursement feasibility becomes a key consideration in go/no-go decisions.Targeted Therapeutics White Paper – Contributed to a white paper outlining the health economic impact of targeted therapeutics, including how to optimize formulary placement and UM strategies with payers. -
Strategy/Management Consultant (Isa Is Now Precisionadvisors)Insight Strategy Advisors Jul 2002 - Jan 2006New York, Ny, UsDe facto US reimbursement and market access expert across auto-immune, oncology and primary care therapeutic areas. One of first two employees to join the firm at its inception. Insight was acquired by Precision Value & Health.Sample Engagements:Patient Flow Analysis – Created a clinical developmnt. opp. assessment through analysis of medical/pharmacy patient claims data, which led to a set of clinical developmnt opportunities for an early stage compound Medical Director Assessment – Provided strategies on how to influence HMO/PBM MDRs to secure initial formulary positioning, defend positioning, and prevent restrictionsPayer Risk Assessment – Led a robust analysis of payer “willingness” to absorb risk for a lifestyle therapy in order to provide Managed Markets team with a list of targeted payer accounts for Contracting OpsBrand Planning – Facilitated strategic brand planning for a late stage biologic with the goal of aligning functional areas within the brand and address potential market barriersDevice Commercial Opportunity Assessment – Identified market capture opps. for two home-use cardiac monitor devices based on epidemiology of target pops., consumer price sensitivity, and reimbursement -
Senior AnalystTrue North Partners (Vc Firm) Mar 2001 - Jul 2002Quantitative and qualitative analysis to support venture capital due diligence (Series C financing) and leading US payer reimbursement and market access consulting projects servicing a diverse range of biotech and pharmaceutical clients
-
ConsultantCsc Healthcare Inc Sep 2000 - Mar 2001Payor/Provider Consulting; PARC; Hospital revenue cycle management; IT contracts management systems -
AnalystAdvisory Board Aug 1998 - Aug 1999Washington, District Of Columbia, UsPayor/Provider & Hospital Benchmarking Research
Vanessa Mirsky Skills
Vanessa Mirsky Education Details
-
University Of ChicagoSocial Sciences -
University Of ChicagoCum Laude
Frequently Asked Questions about Vanessa Mirsky
What company does Vanessa Mirsky work for?
Vanessa Mirsky works for Oneoncology
What is Vanessa Mirsky's role at the current company?
Vanessa Mirsky's current role is Commercial Leader | Global Payer Partnerships | Digital Health & Data Strategy | Access Strategy & Innovation.
What is Vanessa Mirsky's email address?
Vanessa Mirsky's email address is vs****@****ago.edu
What schools did Vanessa Mirsky attend?
Vanessa Mirsky attended University Of Chicago, University Of Chicago.
What skills is Vanessa Mirsky known for?
Vanessa Mirsky has skills like Strategy, Oncology, Market Access, Managed Care, Biotechnology, Healthcare, Pharmaceutical Industry, Clinical Development, Healthcare Consulting, Commercialization, Organizational Design, Health Economics.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial